Wednesday, July 8, 2026

biotech · Chronic Peripheral Neuropathy Pain in Diabetics · Diabetic Peripheral Neuropathy · XTLB

XTL BIOPHARMACEUTICALS

XTL Biopharmaceuticals is a biotech organization headquartered in Raanana, USA. It trades on NYSE under ticker XTLB. Primary therapeutic focus areas include Chronic Peripheral Neuropathy Pain in Diabetics, Diabetic Perip

Raanana, USA HQ
1993 Founded
3 Employees
Public company Type
XTLB · NYSE Ticker
Company details
Status
Public
HQ
Raanana, USA
Founded
1993
Employees
3
Programs
4
Drugs
1
Patents
7
Clinical program

Bicifadine

Phase 2 · small molecule · Chronic Peripheral Neuropathy Pain in Diabetics

Bicifadine for Chronic Peripheral Neuropathy Pain in Diabetics is a Phase 2 program (small_molecule) at XTL BIOPHARMACEUTICALS LTD with 1 ClinicalTrials.gov record(s).

← All XTL BIOPHARMACEUTICALS LTD projects Phase 2 small molecule terminated

Internal code XTL B07-002

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
XTL BIOPHARMACEUTICALS LTD
Phase
Phase 2
Modality
small_molecule
Indication
Chronic Peripheral Neuropathy Pain in Diabetics
Status
terminated
Trials
1

Clinical trials